Chemical biology-based approaches to study adenosine A2A - dopamine D2 receptor heteromers
- PMID:35348986
- PMCID: PMC9832194
- DOI: 10.1007/s11302-022-09860-8
Chemical biology-based approaches to study adenosine A2A - dopamine D2 receptor heteromers
Conflict of interest statement
Manuela Jörg declares that she has no conflict of interest.
Karen J. Gregory declares that she has no conflict of interest.
Similar articles
- Behavioral control by striatal adenosine A2A -dopamine D2 receptor heteromers.Taura J, Valle-León M, Sahlholm K, Watanabe M, Van Craenenbroeck K, Fernández-Dueñas V, Ferré S, Ciruela F.Taura J, et al.Genes Brain Behav. 2018 Apr;17(4):e12432. doi: 10.1111/gbb.12432. Epub 2017 Nov 17.Genes Brain Behav. 2018.PMID:29053217
- Control of Dopamine Signal in High-Order Receptor Complex on Striatal Astrocytes.Amato S, Averna M, Farsetti E, Guidolin D, Pedrazzi M, Gatta E, Candiani S, Maura G, Agnati LF, Cervetto C, Marcoli M.Amato S, et al.Int J Mol Sci. 2024 Aug 7;25(16):8610. doi: 10.3390/ijms25168610.Int J Mol Sci. 2024.PMID:39201299Free PMC article.
- A2A-D2 Heteromers on Striatal Astrocytes: Biochemical and Biophysical Evidence.Pelassa S, Guidolin D, Venturini A, Averna M, Frumento G, Campanini L, Bernardi R, Cortelli P, Buonaura GC, Maura G, Agnati LF, Cervetto C, Marcoli M.Pelassa S, et al.Int J Mol Sci. 2019 May 17;20(10):2457. doi: 10.3390/ijms20102457.Int J Mol Sci. 2019.PMID:31109007Free PMC article.
- Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders.Ferré S, Ciruela F, Canals M, Marcellino D, Burgueno J, Casadó V, Hillion J, Torvinen M, Fanelli F, Benedetti Pd Pd, Goldberg SR, Bouvier M, Fuxe K, Agnati LF, Lluis C, Franco R, Woods A.Ferré S, et al.Parkinsonism Relat Disord. 2004 Jul;10(5):265-71. doi: 10.1016/j.parkreldis.2004.02.014.Parkinsonism Relat Disord. 2004.PMID:15196504Review.
- Striatal astrocytic A2A-D2 receptor-receptor interactions and their role in neuropsychiatric disorders.Cervetto C, Maura G, Guidolin D, Amato S, Ceccoli C, Agnati LF, Marcoli M.Cervetto C, et al.Neuropharmacology. 2023 Oct 1;237:109636. doi: 10.1016/j.neuropharm.2023.109636. Epub 2023 Jun 14.Neuropharmacology. 2023.PMID:37321323Review.
References
- Hillion J, Canals M, Torvinen M, Casado V, Scott R, Terasmaa A, Hansson A, Watson S, Olah ME, Mallol J, Canela EI, Zoli M, Agnati LF, Ibanez CF, Lluis C, Franco R, Ferre S, Fuxe K. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem. 2002;277(20):18091–18097. doi: 10.1074/jbc.M107731200. - DOI - PubMed
- Canals M, Marcellino D, Fanelli F, Ciruela F, de Benedetti P, Goldberg SR, Neve K, Fuxe K, Agnati LF, Woods AS, Ferré S, Lluis C, Bouvier M, Franco R. Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem. 2003;278(47):46741–46749. doi: 10.1074/jbc.M306451200. - DOI - PubMed
- Jörg M, May LT, Mak FS, Lee KC, Miller ND, Scammells PJ, Capuano B. Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of Parkinson's disease. J Med Chem. 2015;58(2):718–738. doi: 10.1021/jm501254d. - DOI - PubMed
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources